
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
“Most innovation happens at the boundaries between different disciplines, and I’m sitting at the boundary between clinicians who work with a drug label and researchers who work with a wide array of targets.” Listen to the Podcast for more coverage.






